| Page 32 | Kisaco Research

Author:

Lauren Baker

Associate
Barnes & Thornburg
... read more

Lauren Baker

Associate
Barnes & Thornburg

Author:

John Cox

Partner
Barnes & Thornburg

With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

... read more

John Cox

Partner
Barnes & Thornburg

With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

Author:

David Kanter

Founder & Executive Director
MLCommons

David co-founded and is the Head of MLPerf for MLCommons, the world leader in building benchmarks for AI. MLCommons is an open engineering consortium with a mission to make AI better for everyone through benchmarks and data. The foundation for MLCommons began with the MLPerf benchmarks in 2018, which rapidly scaled as a set of industry metrics to measure machine learning performance and promote transparency of machine learning techniques. In collaboration with its 125+ members, global technology providers, academics, and researchers, MLCommons is focused on collaborative engineering work that builds tools for the entire AI industry through benchmarks and metrics, public datasets, and measurements for AI Safety. Our software projects are generally available under the Apache 2.0 license and our datasets generally use CC-BY 4.0.

... read more

David Kanter

Founder & Executive Director
MLCommons

David co-founded and is the Head of MLPerf for MLCommons, the world leader in building benchmarks for AI. MLCommons is an open engineering consortium with a mission to make AI better for everyone through benchmarks and data. The foundation for MLCommons began with the MLPerf benchmarks in 2018, which rapidly scaled as a set of industry metrics to measure machine learning performance and promote transparency of machine learning techniques. In collaboration with its 125+ members, global technology providers, academics, and researchers, MLCommons is focused on collaborative engineering work that builds tools for the entire AI industry through benchmarks and metrics, public datasets, and measurements for AI Safety. Our software projects are generally available under the Apache 2.0 license and our datasets generally use CC-BY 4.0.

Saisie Contrefaçon- a New Tool in the UPC Armoury

Author:

Camille Pecnard

Partner
Lavoix
... read more

Camille Pecnard

Partner
Lavoix

Author:

Aude Veinante

European Patent Attorney
Lavoix

Aude assists her clients in defining their patent strategy. Aude drafts new patent applications and monitors grant procedures in France and abroad. Her work also includes conducting patentability, validity and freedom to operate studies as well as forming consultations relative to supplementary protection certificates (SPCs).

Aude performs audits in the pharmaceutical and life science fields and advises her clients in case of patent disputes.

Aude is a member of the AIPPI (International Association for the Protection of Intellectual Property) and the GRAPI (Groupe Rhône-Alpes pour la protection de la Propriété Intellectuelle [Rhône-Alpes Group for the Protection of Intellectual Property]). She is also a lecturer at the Bordeaux National School of Biomolecule Technology.

... read more

Aude Veinante

European Patent Attorney
Lavoix

Aude assists her clients in defining their patent strategy. Aude drafts new patent applications and monitors grant procedures in France and abroad. Her work also includes conducting patentability, validity and freedom to operate studies as well as forming consultations relative to supplementary protection certificates (SPCs).

Aude performs audits in the pharmaceutical and life science fields and advises her clients in case of patent disputes.

Aude is a member of the AIPPI (International Association for the Protection of Intellectual Property) and the GRAPI (Groupe Rhône-Alpes pour la protection de la Propriété Intellectuelle [Rhône-Alpes Group for the Protection of Intellectual Property]). She is also a lecturer at the Bordeaux National School of Biomolecule Technology.

Author:

Pierre-Emmanuel Meynard

Partner
Lavoix
... read more

Pierre-Emmanuel Meynard

Partner
Lavoix

In an increasingly complex global enforcement environment, the interaction between patent office proceedings and patent litigation has taken on new strategic significance. This two-part session explores how decisions in front of the EPO and USPTO impact litigation outcomes and timing, with a focus on high-stakes technology cases.

Part 1: The EPO, the UPC, and the Changing Dynamic of Parallel Proceedings

  • Assess the implications of EPO oppositions running concurrently with UPC litigation—how does the UPC's approach differ from traditional bifurcated systems like Germany?
  • Explore tactical questions: Should you oppose at the EPO or litigate at the UPC—or both? And in what order?
  • Consider the potential for forum shopping and jurisdictional tension between European litigation and opposition venues

Part 2: PTAB Discretionary Denials and Their Impact on U.S. Tech Patent Litigation

  • Unpack the recent shift in USPTO policy regarding discretionary denial of IPRs under NHK-Fintiv and other frameworks
  • Examine how these changes influence litigation timelines, venue strategy, and settlement leverage—especially in tech-heavy districts like WDTX and EDTX
  • Discuss how tech companies are navigating rare appellate routes and increasing pressure to frontload invalidity challenges in district court